Time for a Europe-wide biosimilars strategy, says trade body

A division of Medicines for Europe, the trade group representing the region's generics and biosimilars firms, has called for a new strategy to promote the biosimilars sector.

Noting that patient need for biologics already accounts for 40% of all medicines used in Europe, the group said that policymakers should create a framework and global regulatory system which would enhance the development of new products.

This would help create a wider range of biologic medicines, helping reduce access inequities and lessening the burden of chronic diseases.